Vera Therapeutics, Inc. VERA
Vera Therapeutics, Inc. (Nasdaq: VERA) is a cardio-renal-metabolic drug developer. Its lead program, TRUTAKNA (atacicept-vymj), is in Phase 2 for reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Its next catalyst on record is TRUTAKNA: Supplemental BLA submission for full approval (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TRUTAKNA — Supplemental BLA submission for full approval (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TRUTAKNA (atacicept) IgAN, ORIGIN 3 Phase 3 confirmatory | IgA nephropathy | protein/peptide | Approved |
| atacicept PIONEER Phase 2 | broader IgAN, primary membranous nephropathy, FSGS, minimal change disease | protein/peptide | Phase 2 |
| MAU868 | reactivated BK virus infection | antibody | Phase 2 |
| VT-109 | BAFF/APRIL inhibitor, autoimmune disease | protein/peptide | Pre-clinical |
Recent results and decisions
- Sep 15, 2026met Met all prespecified endpoints at final analysis (n=428): eGFR slope -0.6 vs -5.6 mL/min/1.73m2/yr (diff 5.0, p<0.0001); composite kidney progression HR 0.24 (11 vs 38 events).
TRUTAKNA met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3 trial in adults with primary IgA nephropathy (IgAN) at risk for disease progression.
Filing - Aug 10, 2026approval FDA granted accelerated approval of TRUTAKNA (atacicept-vymj) for adults with primary IgAN at risk for disease progression.
TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression.
Filing - Feb 26, 2026accepted FDA granted priority review to the atacicept BLA for IgAN with a PDUFA date of July 7, 2026.
FDA granted priority review to the atacicept BLA for the treatment of IgAN in adults, and assigned a PDUFA target action date of July 7, 2026
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.